Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
EW
HoldPremium GrowerEdwards Lifesciences Corporation · Healthcare · United States · $52.0B · Avg Vol: $267M/d
COMPANY DESCRIPTION
Edwards Lifesciences Corporation is a global leader in patient-focused medical innovations for structural heart disease and critical care monitoring. The company's competitive moat is its proprietary technologies in heart valves and hemodynamic monitoring, strong intellectual property, and extensive clinical evidence supporting its innovative products. Edwards Lifesciences is a market leader in transcatheter aortic valve replacement (TAVR) and advanced hemodynamic monitoring, benefiting from a highly specialized and growing medical device market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.5B | 5.0B | 5.4B | 6.1B | 10.8% | 6.5B | 6.8B | 7.4B | 10.7% |
| EPS | 2.46 | 2.31 | 6.98 | 1.84 | -9.2% | 1.68 | 2.16 | 2.43 | 14.9% |
| Shares | 608.3M | 601.1M | 588.6M | 580.7M | -4.5% | 576.4M | — | — | — |
| Debt | 691.3M | 685.1M | 700.0M | 705.4M | 0.7% | 704.4M | — | — | — |
| Equity | 5.8B | 6.7B | 10.0B | 10.3B | 21.2% | — | — | — | — |
| Op CF | 1.2B | 895.8M | 542.3M | 1.6B | 9.4% | 1.7B | — | — | — |
| Inv CF | 252.3M | 173.8M | 2.3B | -712.9M | — | — | — | — | — |
| Fin CF | -1.6B | -711.0M | -983.0M | -956.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of EW are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| EW | Edwards Lifesciences Corporation(you) | $52.0B | 64 | Hold |
| SHL.DE | Siemens Healthineers AG | $51.3B | 62 | Hold |
| GEHC | GE HealthCare Technologies Inc. | $32.4B | 63 | Hold |
| 300760.SZ | Shenzhen Mindray Bio-Medical Electronics Co., Ltd. | $29.6B | 63 | Hold |
| BSX | Boston Scientific Corporation | $67.9B | 48 | Hold |
| SYK | Stryker Corporation | $126.8B | 57 | Hold |
| DXCM | DexCom, Inc. | $34.3B | 83 | Strong Buy |
| STE | STERIS plc | $22.8B | 76 | Buy |
| ABT | Abbott Laboratories | $194.6B | 61 | Hold |
| SNN | Smith & Nephew plc | $12.1B | 67 | Buy |
Peer medians: ROE 2.9% · P/E 24.4x · Gross margin 52.6%